Cerus Corporation Invites You to Join a Webcast of Its First Quarter Conference Call

Apr 13, 2001, 01:00 ET from Cerus Corporation

    CONCORD, Calif., April 13 /PRNewswire/ -- In conjunction with Cerus
 Corporation's First Quarter Financial Results release, you are invited to
 listen to its conference call that will be broadcast live over the Internet on
 April 24, 2001 at 4:30 p.m. ET with Stephen Isaacs, President and CEO,
 Greg Schafer, CFO, and Laurence Corash, M.D., VP, Medical Affairs of
 Cerus Corporation (Nasdaq: CERS).
 
     What:     Cerus Corporation First Quarter Financial Results as well as an
               Update on Progress and Future Outlook
 
     When:     Tuesday, April 24, 4:30 p.m. ET
 
     Where:    http://www.videonewswire.com/CERUS/042401/
 
     How:      Live over the Internet -- Simply log on to the web at the
               address above
 
     Contact:  Vivian Dondero of Cerus Corporation, 925-288-6104
 
     Cerus Corporation is developing medical systems and therapeutics based on
 the company's proprietary Helinx technology for inactivating disease-causing
 agents.  Helinx is designed to target and lock DNA or RNA, and has the ability
 to prevent the replication of viruses, bacteria and other pathogens and to
 control cellular proliferation.  The company's most advanced programs are
 focused on systems to enhance the safety of the world's blood supply.  These
 INTERCEPT Blood Systems, based on the Helinx technology, are designed to
 inactivate viruses, bacteria, other pathogens and white blood cells.  The
 Concord, California-based biopharmaceutical company, in collaboration with its
 development and commercialization partner, Baxter Healthcare Corporation, has
 submitted a CE Mark Application for marketing approval of the INTERCEPT
 Platelet System in Europe.  In addition, the company is conducting clinical
 trials of the INTERCEPT Blood Systems in the United States:  a Phase III trial
 for platelets, a Phase III trial for plasma and a Phase Ic trial for red blood
 cells.
 
     NOTE:  Helinx is a trademark of Cerus Corporation
     INTERCEPT Blood System, INTERCEPT Platelet System, INTERCEPT Plasma System
 and INTERCEPT Red Blood Cell System are trademarks of Baxter International,
 Inc. (NYSE:   BAX)
 
     If you are unable to participate during the live webcast, the call will be
 archived for 72 hours on the Website www.cerus.com.
 
     (Minimum Requirements to listen to broadcast:  The RealPlayer software,
 downloadable free from www.real.com/products/player/index.html, and at least a
 14.4Kbps connection to the Internet.  If you experience problems listening to
 the broadcast, send an email to webmaster@vdat.com.)
 
 

SOURCE Cerus Corporation
    CONCORD, Calif., April 13 /PRNewswire/ -- In conjunction with Cerus
 Corporation's First Quarter Financial Results release, you are invited to
 listen to its conference call that will be broadcast live over the Internet on
 April 24, 2001 at 4:30 p.m. ET with Stephen Isaacs, President and CEO,
 Greg Schafer, CFO, and Laurence Corash, M.D., VP, Medical Affairs of
 Cerus Corporation (Nasdaq: CERS).
 
     What:     Cerus Corporation First Quarter Financial Results as well as an
               Update on Progress and Future Outlook
 
     When:     Tuesday, April 24, 4:30 p.m. ET
 
     Where:    http://www.videonewswire.com/CERUS/042401/
 
     How:      Live over the Internet -- Simply log on to the web at the
               address above
 
     Contact:  Vivian Dondero of Cerus Corporation, 925-288-6104
 
     Cerus Corporation is developing medical systems and therapeutics based on
 the company's proprietary Helinx technology for inactivating disease-causing
 agents.  Helinx is designed to target and lock DNA or RNA, and has the ability
 to prevent the replication of viruses, bacteria and other pathogens and to
 control cellular proliferation.  The company's most advanced programs are
 focused on systems to enhance the safety of the world's blood supply.  These
 INTERCEPT Blood Systems, based on the Helinx technology, are designed to
 inactivate viruses, bacteria, other pathogens and white blood cells.  The
 Concord, California-based biopharmaceutical company, in collaboration with its
 development and commercialization partner, Baxter Healthcare Corporation, has
 submitted a CE Mark Application for marketing approval of the INTERCEPT
 Platelet System in Europe.  In addition, the company is conducting clinical
 trials of the INTERCEPT Blood Systems in the United States:  a Phase III trial
 for platelets, a Phase III trial for plasma and a Phase Ic trial for red blood
 cells.
 
     NOTE:  Helinx is a trademark of Cerus Corporation
     INTERCEPT Blood System, INTERCEPT Platelet System, INTERCEPT Plasma System
 and INTERCEPT Red Blood Cell System are trademarks of Baxter International,
 Inc. (NYSE:   BAX)
 
     If you are unable to participate during the live webcast, the call will be
 archived for 72 hours on the Website www.cerus.com.
 
     (Minimum Requirements to listen to broadcast:  The RealPlayer software,
 downloadable free from www.real.com/products/player/index.html, and at least a
 14.4Kbps connection to the Internet.  If you experience problems listening to
 the broadcast, send an email to webmaster@vdat.com.)
 
 SOURCE  Cerus Corporation